A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Sponsor
Takeda
Study ID
NCT05100056
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — OTHER
    This is a non-interventional study.

Study Details

The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.

Key Dates

First listed
Oct 29, 2021
Start date
Mar 8, 2022
Status verified
May 2026
Primary completion
Jan 13, 2027
Completion
Jan 13, 2027

Study Design

Enrollment
70 participants (estimated)

Arms

  • Arm: HL Participants: BV Salvage Pre-ASCT
    Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.
  • Arm: HL Participants: BV Consolidation Treatment Post-ASCT
    Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.

Primary Outcome Measure

Progression Free Survival (PFS) as Assessed by Investigator [ Time Frame: From initiation of BV treatment post-ASCT until disease progression or relapse, or death (up to 36 months) ]

Central Contacts

Related Studies